RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
Molecular remission can be attained in relapsed or refractory chronic lymphocytic leukemia (CLL) and follicular lymphomas after reduced intensity conditioning (RIC) and allogeneic stem cell transplantation (allo-SCT).
2004-01-01 Farina, L; Carrabba, M; Dodero, A; Rizzo, E; Zorzan, E; Ciceri, F; Locasciulli, A; Olivieri, Attilio; Rambaldi, A; Tarella, C; Santoro, A; Patriarca, F; Bacigalupo, A; Corradini, P.
Molecular remission in relapsed/refractory chronic lymphocytic leukaemia and follicular lymphomas treated with RIC-allogeneic stem cell transplantation correlates with a better disease-free survival
2005-01-01 Farina, L; Carrabba, M; Milani, R; Dodero, A; Rizzo, E; Ciceri, F; Locasciulli, A; Santoro, A; Olivieri, Attilio; Tarella, C; Corradini, P.
MONITORING STRATEGY OF ANTHRACYCLINES CARDOTOXICITIES BY BIOMARKERS AND ECOCARDIOGRAPHY IN 104 PRESPECTIVES PATIENTS AFFECTED BY LYMPHOMA
2015-01-01 G. Gini, J. Olivieri; C., Bocci; S., Cacciagiù; M., Sampaolo; S., Trappolini; Olivieri, Attilio; M., Offidani; S., Rupoli; Poloni, Antonella; D., Capelli; M., Montanari; I., Scortechini; G. P., Perna; Leoni, Pietro
Multicenter prospective randomized GITMO trial comparing high dose sequential chemotherapy with autografting and CHOP both supplemented with Rituximab as frontline therapy for high-risk follicular lymphoma (FL) patients: An interim analysis.
2002-01-01 Ladetto, M; Ricca, I; Benedetti, F; Vitolo, U; Liberati, M; Musso, M; Callea, V; Gallamini, A; Patti, C; Pavone, V; Almici, C; Di Raimondo, F; Fioritoni, G; Olivieri, Attilio; Pogliani, Em; De Souza, Ca; Majolino, I; Boccadoro, M; Gianni, Am; Pileri, A; Corradini, P; Tarella, C.
Multicenter prospective randomized GITMO trial comparing high dose sequential chemotherapy with autografting and CHOP both supplemented with rituximab in poor-risk follicular lymphoma: early evaluation on treatment feasibility and response rate
2003-01-01 Ladetto, M; Ricca, I; Benedetti, F; Liberati, M; Vitolo, U; Musso, M; Gallamini, A; Callea, V; Pavone, V; Almici, C; Di Raimondo, F; De Sousa, C; Fioritoni, G; Majolino, I; Olivieri, Attilio; Patti, C; Pogliani, E; Astolfi, M; Boccadoro, M; Gianni, Am; Corradini, P; Tarella, C.
Multicentre randomised GITMO-IIL trial in high-risk follicular lymphoma at diagnosis: rituximab-supplemented high-dose sequential chemotherapy is superior to CHOP-R in molecular remissions rate, EFS and PFS
2007-01-01 Ladetto, M.; De Marco, F.; Benedetti, F.; Vitolo, U.; Patti, C.; Rambaldi, A.; Liberati, A. M.; Musso, M.; Pulsoni, A.; Olivieri, Attilio; Pavone, E.; Pogliani, E.; Scalabrini, D. Rota; Gallamini, A.; Callea, V.; Ricca, I.; Boccadoro, M.; Majolino, I.; Corradini, P.; Gianni, A. M.; Tarella, C.
Neurologic Complications IIN 169 Consecutive Allogeneic Stem Cell Transplants: Etiology, Clinical Syndromes and Outcome
2020-01-01 Scortechini, I; Inglese, E; Poiani, M; Saraceni, F; Mancini, G; Urbano, G; Federici, I; Mariani, M; Micucci, G; Olivieri, A; Polonara, G
No increase of early toxicity or TRM in Philadelphia positive CML patients pre-treated with imatinib: a retrospective GITMO and ICSG study
2005-01-01 Bassi, S; Bonifazi, F; Tifibelli, M; Marenco, P; Olivieri, Attilio; Lanino, E; Bonini, A; Laszlo, D; Raimondi, R; Rosti, G; Baccarani, M; Bandini, G; Bruno, B; Bacigalupo, A.
Outcome of AML patients receiving autologous stem cell transplantation (ASCT), according to cytogenetics and molecular markers: a GITMO* survey on 866 patients transplanted in CR1
2013-01-01 Olivieri, Attilio; Bruno, B; Lemoli, R; Meloni, G; Arcese, W; Falda, M; Milone, G; Cortelezzi, A; Ciceri, F; Alessandrino, Ep; Specchia, G; Saraceni, F; Scime, R; Raimondi, R; Leone, G; Bosi, A; Rambaldi, A.
OVEREXPRESSION OF CDKN2B IS ASSOCIATED WITH REDUCED PROLIFERATIVE POTENTIAL IN MESENCHYMAL STEM CELL FROM HIGH-RISK MYELODYSPLASTIC SYNDROME
2014-01-01 Mattiucci, Domenico; Maurizi, G; Amatori, S; Costantini, B; Mariani, M; Mancini, Stefania; Fanelli, M; Olivieri, Attilio; Leoni, Pietro; Poloni, Antonella
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Molecular remission can be attained in relapsed or refractory chronic lymphocytic leukemia (CLL) and follicular lymphomas after reduced intensity conditioning (RIC) and allogeneic stem cell transplantation (allo-SCT). | 1-gen-2004 | Farina, L; Carrabba, M; Dodero, A; Rizzo, E; Zorzan, E; Ciceri, F; Locasciulli, A; Olivieri, Attilio; Rambaldi, A; Tarella, C; Santoro, A; Patriarca, F; Bacigalupo, A; Corradini, P. | |
Molecular remission in relapsed/refractory chronic lymphocytic leukaemia and follicular lymphomas treated with RIC-allogeneic stem cell transplantation correlates with a better disease-free survival | 1-gen-2005 | Farina, L; Carrabba, M; Milani, R; Dodero, A; Rizzo, E; Ciceri, F; Locasciulli, A; Santoro, A; Olivieri, Attilio; Tarella, C; Corradini, P. | |
MONITORING STRATEGY OF ANTHRACYCLINES CARDOTOXICITIES BY BIOMARKERS AND ECOCARDIOGRAPHY IN 104 PRESPECTIVES PATIENTS AFFECTED BY LYMPHOMA | 1-gen-2015 | G. Gini, J. Olivieri; C., Bocci; S., Cacciagiù; M., Sampaolo; S., Trappolini; Olivieri, Attilio; M., Offidani; S., Rupoli; Poloni, Antonella; D., Capelli; M., Montanari; I., Scortechini; G. P., Perna; Leoni, Pietro | |
Multicenter prospective randomized GITMO trial comparing high dose sequential chemotherapy with autografting and CHOP both supplemented with Rituximab as frontline therapy for high-risk follicular lymphoma (FL) patients: An interim analysis. | 1-gen-2002 | Ladetto, M; Ricca, I; Benedetti, F; Vitolo, U; Liberati, M; Musso, M; Callea, V; Gallamini, A; Patti, C; Pavone, V; Almici, C; Di Raimondo, F; Fioritoni, G; Olivieri, Attilio; Pogliani, Em; De Souza, Ca; Majolino, I; Boccadoro, M; Gianni, Am; Pileri, A; Corradini, P; Tarella, C. | |
Multicenter prospective randomized GITMO trial comparing high dose sequential chemotherapy with autografting and CHOP both supplemented with rituximab in poor-risk follicular lymphoma: early evaluation on treatment feasibility and response rate | 1-gen-2003 | Ladetto, M; Ricca, I; Benedetti, F; Liberati, M; Vitolo, U; Musso, M; Gallamini, A; Callea, V; Pavone, V; Almici, C; Di Raimondo, F; De Sousa, C; Fioritoni, G; Majolino, I; Olivieri, Attilio; Patti, C; Pogliani, E; Astolfi, M; Boccadoro, M; Gianni, Am; Corradini, P; Tarella, C. | |
Multicentre randomised GITMO-IIL trial in high-risk follicular lymphoma at diagnosis: rituximab-supplemented high-dose sequential chemotherapy is superior to CHOP-R in molecular remissions rate, EFS and PFS | 1-gen-2007 | Ladetto, M.; De Marco, F.; Benedetti, F.; Vitolo, U.; Patti, C.; Rambaldi, A.; Liberati, A. M.; Musso, M.; Pulsoni, A.; Olivieri, Attilio; Pavone, E.; Pogliani, E.; Scalabrini, D. Rota; Gallamini, A.; Callea, V.; Ricca, I.; Boccadoro, M.; Majolino, I.; Corradini, P.; Gianni, A. M.; Tarella, C. | |
Neurologic Complications IIN 169 Consecutive Allogeneic Stem Cell Transplants: Etiology, Clinical Syndromes and Outcome | 1-gen-2020 | Scortechini, I; Inglese, E; Poiani, M; Saraceni, F; Mancini, G; Urbano, G; Federici, I; Mariani, M; Micucci, G; Olivieri, A; Polonara, G | |
No increase of early toxicity or TRM in Philadelphia positive CML patients pre-treated with imatinib: a retrospective GITMO and ICSG study | 1-gen-2005 | Bassi, S; Bonifazi, F; Tifibelli, M; Marenco, P; Olivieri, Attilio; Lanino, E; Bonini, A; Laszlo, D; Raimondi, R; Rosti, G; Baccarani, M; Bandini, G; Bruno, B; Bacigalupo, A. | |
Outcome of AML patients receiving autologous stem cell transplantation (ASCT), according to cytogenetics and molecular markers: a GITMO* survey on 866 patients transplanted in CR1 | 1-gen-2013 | Olivieri, Attilio; Bruno, B; Lemoli, R; Meloni, G; Arcese, W; Falda, M; Milone, G; Cortelezzi, A; Ciceri, F; Alessandrino, Ep; Specchia, G; Saraceni, F; Scime, R; Raimondi, R; Leone, G; Bosi, A; Rambaldi, A. | |
OVEREXPRESSION OF CDKN2B IS ASSOCIATED WITH REDUCED PROLIFERATIVE POTENTIAL IN MESENCHYMAL STEM CELL FROM HIGH-RISK MYELODYSPLASTIC SYNDROME | 1-gen-2014 | Mattiucci, Domenico; Maurizi, G; Amatori, S; Costantini, B; Mariani, M; Mancini, Stefania; Fanelli, M; Olivieri, Attilio; Leoni, Pietro; Poloni, Antonella |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 1 Contributo su Rivista 158
- 1 Contributo su Rivista::1.5 Abst... 158
Data di pubblicazione
- 2020 - 2022 9
- 2010 - 2019 43
- 2002 - 2009 106
Rivista
- BONE MARROW TRANSPLANTATION 62
- BLOOD 52
- HAEMATOLOGICA 27
- HAEMATOLOGICA 8
- CLINICAL LYMPHOMA & MYELOMA 2
- ANNALS OF THE RHEUMATIC DISEASES 1
- BIOCHIMICA CLINICA 1
- BLOOD 1
- BONE MARROW TRANSPLANTATION 1
- HEMASPHERE 1
Lingua
- eng 23
Accesso al fulltext
- no fulltext 158